Mortality implications of primary percutaneous coronary intervention treatment delays: Insights from the assessment of pexelizumab in acute myocardial infarction trial

Circulation: Cardiovascular Quality and Outcomes

Volumn 4, Issue 2, 2011, Pages 183-192

  Hudson, Michael P ^a   Armstrong, Paul W ^b   O'Neil, William W ^c   Stebbins, Amanda L ^d   Douglas, Weaver W ^a   Widimsky, Petr ^f   Aylward, Philip E ^g   Ruzyllo, Witold ^h   Holmes, David ^e   Mahaffey, Kenneth W ^a   Granger, Christopher B ^d  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e CHARLES UNIVERSITY   (Czech Republic)

^f FLINDERS UNIVERSITY   (Australia)

^g INSTITUTE OF CARDIOLOGY   (Poland)

^h MAYO CLINIC   (United States)

Author keywords

Angioplasty; Mortality; Myocardial infarction; Reperfusion

Indexed keywords

PEXELIZUMAB; PLACEBO;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD FLOW; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART RATE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; SYSTOLIC BLOOD PRESSURE; THERAPY DELAY; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; COMPLEMENT C5; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SEX FACTORS; SINGLE-CHAIN ANTIBODIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959766059     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.945311     Document Type: Article

References (24)

1. Boden WE, Eagle K, Granger CB. Reperfusion strategies in acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2007; 50:917-929.
2. Stone GW. Angioplasty strategies in ST-segment elevation myocardial infarction. Circulation. 2008;118:538-551.
3. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004. Available at www.acc.org/clinical/guidelines/stemi/ index.pdf.
4. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomized trials. Lancet. 2003;361:13-20. (Pubitemid 36050955)
5. The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Management of the acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart Journal. 2008;29: 2909-2945.
6. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, Gore JM, Weaver WD, Rodgers WJ, Tiefenbrunn AJ. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941-2947. (Pubitemid 30414505)
7. Zijlstra F, Patel A, Jones M, Grines CL, Ellis S, Garcia E, Grinfeld L, Gibbons RJ, Riberio EE, Ribbichini F, Granger C, Akhras F, Weaver WD, Simes RJ. for the PCAT collaboration. Clinical characteristics and outcome of patients with early (>2 h), intermediate (2-4 h), and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2002;22:550-557. (Pubitemid 35192202)
8. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcomes in patients with acute myocardial infarction: results from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO IIb) Trial. Circulation. 1999;100:14-20. (Pubitemid 29297934)
9. De Luca G, Suryapranata H, Zijlstra F, van't Hof AWJ, Hoorntje JCA, Gosselink ATM, Dambrink JH, deBoer MJ. on behalf of the ZWOLLE Myocardial Infarction Study Group. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2003;42:991-997. (Pubitemid 37108581)
10. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardialinfarction: every minute of delay counts. Circulation. 2004;109: 1223-1225. (Pubitemid 38372780)
11. McNamara RL, Wang Y, Herrin J, Curtis JP, Bradley EH, Magid DJ, Peterson ED, Blaney M, Frederick PD, Krumholz HM. for the NRMI Investigators. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2006; 47:2180-2186. (Pubitemid 43810139)
12. Brodie BR, Hansen C, Stuckey TD, Richter S, VerSteeg DS, Gupta N, Downey WE, Pulsipher M. Door-to-balloon time with primary percutaneous intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. J Am Coll of Cardiol. 2006;47:289-295. (Pubitemid 43063244)
13. Brodie BR, Stone GW, Cox DA, Stuckey TD, Turco M, Tcheng JE, Berger P, Mehran R, McLaughlin M, Costantini C, Lansky A, Grines C. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. Am Heart J. 2006;151:1231-1238. (Pubitemid 43866606)
14. Stone GW, Dixon SR, Grines CL, Cox DA, Webb JG, Brodie BR, Griffin JJ, Martin JL, Fahy M, Mehran R, Miller TD, Gibbons RJ, O'Neill W. Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. Am J Cardiol. 2007;100:1370-1375. (Pubitemid 47592901)
15. The APEX AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. JAMA. 2007;297:43-51.
16. Buller CE, Fu Y, Mahaffey KW, Todaro TG, Adams P, Westerhout DM, White HD, van't Hof AWJ, Van de Werf FJ, Wagner GS, Granger CB, Armstrong PW. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. Circulation. 2008;118:1335-1346.
17. Schroder R, Wegscheider K, Schroder K, Dissman R, Meyer-Sabellek W. Extent of early ST-segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and A sensitive measure to compare thrombolytic regimens: A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol. 1995;26:1657-1664.
18. The TIMI Study Group. Thrombolysis in Myocardial Infarction (TIMI) trial: phase 1 findings. N Engl J Med. 1985;312:932-936.
19. Angeja BG, Gibson CM, Chin R, Frederick PD, Every NR, Ross AM, Stone GW, Barron HV. for the Participants in the National Registry of Myocardial Infarction 2-3. Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol. 2002;89:1156-1161.
20. Goldberg RJ, Steg PG, Sadiq I, Granger CB, Jackson EA, Budaj A, Brieger D, Avezum A, Goodman S. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease. (The Grace Registry). Am J Cardiol. 2002;89:791-796. (Pubitemid 34241453)
21. Keeley EC, Grines CL. The case for emergency transfer for primary percutaneous coronary intervention. Circulation. 2005;112:3520-3532. (Pubitemid 43739569)
22. Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med. 2007;357: 163-238.
23. Bradley EH, Curry LA, Webster TR, Mattera JA, Roumanis SA, Radford MJ, McNamara RL, Barton BA, Berg DN, Krumholz HM. Achieving rapid door-to-balloon times, how top hospitals improve complex clinical systems. Circulation. 2006;113:1079-1085.
24. Sheiban I, Fragasso G, Rosano GMC, Dharmadhikari A, Tzifos V, Pagnotta P, Chierchia SL, Trevi G. Time course and determinants of left ventricular functional recovery after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol. 2001;38:464-471. (Pubitemid 32721775)